Filter
26
Filtered Results: 26
Text search:
molnupiravir
Featured
Recommendations
9
Language
Document type
Guidelines
11
Fact sheets
6
Studies & Reports
5
Strategic & Response Plan
2
Manuals
1
Resource Platforms
1
Countries / Regions
Ukraine
3
Latin America and the Carribbean
3
Global
2
El Salvador
1
Africa
1
Paraguay
1
Authors & Publishers
Publication Years
Category
COVID-19
7
Guidelines
3
Infection Control & Prevention (IPC)
1
Medical Devices & Equipment
1
Humanitarian Crisis
1
Health Systems
1
Pharmacy & Technologies
1
Toolboxes
Clinical Guidelines
14
Country specific documents
2
COVAX Initiative
2
Public Health
1
Global Impact: Socio-economic, health services, TB & HIV
1
Scientific & Research Studies
1
Hospital Readiness/Essential Health Services
1
Access & Strategy
1
Fair Allocation & Ethical Aspects
1
SARS-CoV-2 Variants
1
Essential Medicines
1
Prices and Patents
1
Ukraine
1
Situation Reports & Updates
1
Appeals & Response Plans
1
Global Overview
1
Human Rights & the Right to Health
1
Molnupiravir for COVID-19
recommended
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
Administration of Molnupiravir for COVID-19
recommended
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,...
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for...
This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi...
The World Health Organization (WHO) recognizes the challenges countries face for maintaining their COVID-19 response while addressing competing public health challenges, conflicts, climate change and economic crises. WHO continues to support countries in adjusting COVID-19 strategies to reflect succ...
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
26 de abril del 2022. La Organización Panamericana de la Salud presenta estas consideraciones con el fin de apoyar la toma de decisiones relativa al manejo de pacientes con COVID-19 en la Región de las Américas. Las recomendaciones tienen en cuenta la evidencia más reciente, el estado de vacunac...
Guía de tratamiento farmacológico y manejo deescenarios clínicos de casos de COVID-19 – enero 2022 Guía de tratamiento farmacológico y manejo deLeer más
The military offensive by the Russian Federation in Ukraine which began February 2022 has triggered one of the world’s fastest-growing displacement and humanitarian crisis, with geopolitical and economic ripples felt across the globe. The ongoing war has caused large-scale disruptions to the deliv...
Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in-
come countries (LMICs). While the COVID-19 pan...
Der Krieg der Russischen Föderation gegen die Ukraine hat Leid und Verwüstung in einem in der Europäischen Region der WHO seit Jahrzehnten nicht gekannten Ausmaß verursacht. In der Ukraine spielt sich eine sich rasch entwickelnde humanitäre und Flüchtlingskrise ab, deren geopolitische und wirt...
Reseña normativa de la OMS:
This bi-weekly brief details the latest developments in scientific knowledge and public health policy from around the world as well as updates to the COVID-19-related guidance from Africa CDC, WHO and other public health agencies.
31 Oct 2022 his plan outlines how the ACT-Accelerator will support countries as the world transitions to long-term COVID-19 control.
Recognizing the evolving nature of the COVID-19 virus and pandemic, the plan outlines changes to ACT-A’s set-up and ways of working, to ensure countries co...
This report’s central premise is that diagnostics and therapeutics, and associated test to treat strategies, are fundamental components of the pandemic response, both for COVID-19 and for future health threats. Two years into the COVID-19 pandemic, this report reflects on the main challenges and k...
3 March 2022
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an ...
